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ABSTRACT 
Synthetic strategies towards obtaining natural products and their derivatives provide a 
wealth of research for organic chemists. The two perspectives provided utilize methodology 
in the development towards the synthesis of Tamiflu analogs and the isolation of active 
fractions from a plant extraction of Prunella vulgaris. 
Amino esters, such as Tamiflu, are known to have antiviral activity. Using as [3+3] 
annulation, several different nitro and amino analogs of Tamiflu have been concisely 
synthesized. The annulation is achieved using a Homer-Wadsworth-Emmons type reagent 
and an (^-unsaturated aldehyde or ketone in the presence of DBU. 
Prunella vulgaris is a Chinese herb that has been shown to have biological activity. In 
this study, the anti-HIV activity and anti-inflammatory activities were studied. The 
preliminary results obtained were sufficient to warrant further study of the biological activity 
of Prunella vulgaris. 
1 
CHAPTER 1 
Analogs of Tamiflu 
Introduction 
Tamiflu is a very selective and potent inhibitor of influenza neuraminidase at 
nanomolar concentrations and as a result was launched as a drug in 1999.1 It is used as an 
oral treatment for the prevention of influenza virus infections, such as bird flu. Tamiflu is 
effective against both influenza A and B viruses and was discovered by Gilead Sciences2'3 in 
1995 and developed by Hoffmann-LaRoche.4 The prodrug is commercially available as a 
capsule that contains 75 milligrams of oseltamivir for oral use and as a powder for oral 
suspension, which, when it is constituted with water in the required amount, contains 12 
mg/mL of oseltamivir base.5 
C02Et 
XÔ I^OV ''NH2 H3PO4 
' NHAc 
1 
Figure 1. Tamiflu (Oseltamivir phosphate) 
The first antiviral treatments for influenza were amantadine and rimantadine, which 
are inhibitors of the M2 ion channel protein contained within the influenza virus. Both agents 
have been shown to be effective, but they are only active against influenza virus A, because 
influenza virus B does not possess an M2 protein.6 Another disadvantage of this treatment 
system is that adamantine-resistant influenza A viruses emerge readily due to mutations after 
use of both agents.7 In contrast, the mutations required to give resistance to the 
neuraminidase inhibitors are at the highly conserved active site of the neuraminidase enzyme. 
This therefore allows the neuraminidase inhibitors to be active against all influenza A and B 
subtypes. 
2 
Synthesis of Tamiflu 
The two starting materials used in the synthesis of Tamiflu are shikimic acid and 
quinic acid. Shikimic acid is obtained by extraction of the Chinese star anise or from 
fermentation where a genetically engineered E. coli strain is used.1 Quinic acid is one of the 
by-products that is obtained from the extraction of quinine for tonic water from the bark of 
the African cinchona tree.1 Shikimic acid is preferred as a starting material over quinic acid, 
because it already has the carbon-carbon double bond functionality that is required in the 
target molecule. 
In the technical synthesis of Tamiflu, a diethyl ketal intermediate 12 is obtained from 
shikimic acid in 3 steps (Figure 2). The 3-pentyl ether side chain is introduced by the 
regioselective ring opening of the ketal intermediate. This step is followed by a base-induced 
epoxide ring closure to form the key intermediate 14 toward the synthesis of Tamiflu. The 
epoxide is transformed to a 1,2-diamino derivative involving azide chemistry, which is 
potentially hazardous. 
3 
(-)-Shikimic acid 
Sources: 
-Extraction from 
Chinese star anis 
H0V' 
HO,,. 
OH 
C02H 
3 steps 
"Azic 
Cher 
61% AcHN' 
Tamiflu 
-Fermentation 
Biotechnology 
1. Et3SiH, TiCI4 
C°2Et 2. NaHC03 aq. 
Ôv' 
OMs 
2 
"Azide" \ 
Chemistry 
5 steps 
27-29% 
AcHN 
5 steps 
HOv" 
HO/,. 
OH 
(-)-Quinic acid 
O,./^/C02Et 
NH2H3PO4 
Tamiflu 
Source: 
-Extraction from the 
bark of Cinchona tree 
Figure 2. Technical Synthesis of Tamiflu 
The first synthesis of Tamiflu involved formation of a diketal intermediate 2, which 
was first obtained from quinic acid in 5 steps and later from shikimic acid in 4 steps. The 
diketal was then opened regioselectively to introduce the pentyl ether functionality, which 
was followed by epoxidation to give a key intermediate in the synthesis of Tamiflu. The 
amino groups were then introduced by azide chemistry, which involved the formation of 
aziridines. 
Other strategies for introduction of the two amino groups present in Tamiflu that were azide-
free were later developed. The first type of azide-free chemistry involved the use of an allyl 
amine.8 In the second generation of the azide-free synthesis of Tamiflu, a tert-butylamine 
group was introduced. This led to an increased yield (61 %) for the synthesis of Tamiflu from 
the epoxide precursor 3 (Figure 2).9 
4 
Two different syntheses of Tamiflu have been reported in the literature recently by 
Corey et al10 and Shibasaki etaln The key steps in the Corey synthesis are shown in Figure 
3. The first step, a Diels Alder reaction, uses butadiene and trifluoroethyl aery late. 
CO2CH2CF 3 0 
BocN—& 
5 O 
a NBA, MeCN C02Et -40 °C, 4h BocHN' 
NHAc 
5 mol % SnBr4 Br// AcHN 
BocHNv' 
not optimized 
H3N° ^^C02Et 
H2PO4" 1 
+ 
6 
Figure 3. Corey Synthesis 
It is followed by modification of the ester to give amide 4. lodol actamizati on of 4, protection 
and then dehydroiodination gave compound 5. Allylic bromination of 5 and treatment with 
CsCO] gave diene ethyl ester 6. Conversion of 6 to diamide 7 involves a novel SnBr4 
catalyzed bromoacetamidation using 7V-bromoacetamide (NBA) that is regioselective and 
stereoselective. Compound 7 was cyclized to an 7V-acetylaziridine and regioselectively 
opened with 3-pentanol. Removal of the protecting group and salt formation with H3PO4 
gave Tamiflu in 11 steps. The last four steps have not been optimized, meaning that no 
overall yield was reported. 
The Shibasaki synthesis also uses aziridine chemistry, where the first key step is a 
catalytic enantioselective ring opening of aziridine 8 using TMSN3 to give compound 9 
(Figure 4). 
5 
Y(OPr)3 (x mol %) 
<Ph)2^X^(2x mo1 %) 
TMSN3 
CH3CH2CN 
NHAc NHBoc 
NHBoc 
avNHBoc 'NHBoc 
10 
Et02C v "NH2H3PO4 
11 1 
Figure 4. Shibasaki Synthesis 
The symmetrical diamide 10 was then synthesized from 9 in 4 steps. Allylic oxidation and 
1,4-addition of TMSCN gave ketonitrile 11. The keto group was selectively reduced to an 
alcohol after which the pentyl ether was introduced. Boc deprotection using TFA, then 
protection of the less sterically hindered amine was followed by acetylation. Conversion of 
the nitrile to the ester was associated with removal of the protecting group. Salt formation 
gave Tamiflu, 1, in 7 steps from 11. The Shibasaki synthesis took 21 steps with a 50 % yield 
of 1 from the penultimate step. 
Methodology 
Our strategy was to make analogs of Tamiflu in as few steps as possible. The key step 
involved a [3+3] annulation using an Horner-Wadsworth-Emmons type reagent 13 and an 
(^-unsaturated aldehyde or ketone 14 in the presence of DBU and CH2CI2 as solvent. The 
two main steps that make this reaction successful are a Michael addition that is followed by 
an intramolecular Wittig. 
C02Et N02 O 
R1 
R1 
''N02 (Et0)2P/xC02Et R2 
R2 O 
12: R =H, R-| =H, R2 =CH3 13 14 
6 
First, ethyl-2-(diethoxyphosphoryl)acrylate, a known compound, had to be made.12 
This reaction was monitored by proton NMR to make sure the hydroxymethyl intermediate 
was obtained before proceeding with the next step, a PTSA-mediated dehydration. All of the 
triethylphosphonoacetate had to be converted to this intermediate; otherwise, a mixture of 
starting material and product would be obtained. 
1. (H2CO)x /oh 
OEt cat, piperidine I QEt 2. cat. TsOH 
(EtO)2P^X|]/ MeOH (EtO)2P^|j^ Toluene (EtO)2P 
Ô O reflux Ô O reflux Ô O 
100% 
9 
Phosphonate 13 also had to be made and its synthesis has not been previously 
reported in the literature. This reagent was made from the Michael addition of nitromethane 
to ethyl 2-(diethoxyphosphoryl)acrylate. Other nitroalkanes have been successfully reacted 
with ethyl 2-(diethoxyphosphoryl)acrylate to give ethyl 2-diethoxyphosphoryl-4-
nitroalkanoates using NaH in THF.13 The first question was whether the reaction would occur 
with nitromethane. The desired product was not obtained with NaH in THF and other bases, 
such as NaOMe and DBU, were used to see if the reaction would occur successfully. The 
best reaction conditions were obtained using NaOMe/MeOH with a 54% yield. 
7 
(EtO)2P' "°E{ 
O O 
CH3N02 
NaH 
(EtO)2P 
THF 
rt. 
24 hr 
CH3NO2 
DBU 
13 
CH2CI2 
20% 
CH3NO2 
NaOMe 
13 
MeOH 
54 % 
13 
Crotonaldehyde, an a,P-unsaturated aldehyde, was used to determine the optimal 
reaction conditions under which the annulation would occur with phosphonate 13. Initially, 
the goal was to make the dianion using two equivalents of bases, such as fBuOK or NaOMe, 
so that the Wittig reaction would occur first as shown in Figure 5. 
O Oy O© C02Et C02Et 
(EtO)2R C02Et (EtO)2Px C02Et 
©o^ 
^NO2 
CH3 
F?(OEt)2 
C02Et 
Figure 5. Mechanism resulting from dianion 
After this did not occur successfully, the next strategy was to use one equivalent of 
base. The desired product was not obtained. Instead, intermediates that could potentially lead 
to the product were observed. One of the intermediates arose from the Michael addition, 15, 
while the other intermediate arose from Michael addition and cyclization, 16. 
8 
(Et0)2P\X02Et (EtO)2Px C02Et 
HO. 
15 16 
These reaction intermediates support the mechanism in Figure 6, which is proposed for the 
overall reaction. 
O 
(Et0)2P^/C02Et (EtO)2Ps ,C02Et (Et0)2P\.C02Et 
,©f 
ft (EtO)2R C02Et 
0O„ 
P(OEt)2 C02Et 
Figure 6. Mechanism for overall reaction 
Initially, most of the reactions were carried out from 0 °C to 25 °C. To push the 
reaction further to completion, the reaction mixture was heated under reflux conditions. The 
desired product was successfully obtained using DBU under the conditions shown for the 
main reaction in Table 1. 
The next step was to see what other (^-unsaturated aldehydes or ketones would react 
with phosphonate 13. Most of the (^-unsaturated aldehydes or ketones used were 
commercially available, but some were synthesized in 2 to 3 steps. Several analogs of 
Tamiflu were synthesized successfully using the [3+3] annulation as shown in Table 1. 
9 
Table 1. 
NO2 O C02Et 
* 
RI^ 
DBU ^ RÂ (EtO)2P C02Et 
6 
FV CH2CI2 
0 °C-» 50 °C 
RI^^N02 
R2 
13 14 12 
Analog R Ri Rz % Yield cis/trans 
12a H H Me 74 1:3 
12b H Me Me 24 1:1 
12c H H Ph 59 1:3 
a12d Me H Ph 26 trans only 
b12e H H 2-Furyl 60 trans only 
12f H H (CH2)gCH3 64 1:3 
b12g 
12h 
H 
H 
(0% 
CH2SCH2 
45 
36 
C 
d 
a Solvent used was CH3CN 
b Reaction carried out at rt 
c Ratio of exo to endo is 9:1 
d Ratio of exo to endo is 4:1 
All the products in Table 1, except for analog 12b, were predominantly one 
diastereomer. Proton NMR data supports a trans-diequatorial relationship between the nitro 
group and R2. The trans isomer was the major product isolated for analogs 12a and 12c and 
was the only isomer isolated for 12d and 12e. In the case of the bicyclic products, 12g and 
12h, the nitro group appears to be on the exo face of the fused bicyclic ring system. In the 
nitro analog 12g, the ratio of exo to endo nitro group was 9:1 and in analog 12h the ratio of 
exo to endo for the nitro group was 4:1. Table 2 shows other aldehydes and ketones that 
were also reacted with phosphonate 13, but the reactions did not occur successfully. 
10 
NO2 
Table 2. 
O CO, Et 
(EtO)2P C02Et k2 
6 
13 
+ 
CH2CI2 r NO2 
0 °C-»- 50 °C 
Aldehyde/Ketone 
methacrolein 
acrolein 
Methyl cronoate 
3 -( 1,3 -dihydro-1,3 -dioxo-2H-isoindol-2-yl)-2-propenal 
Mesityl oxide 
4-(2-furyl)-3 -buten-2-one 
methyl vinyl ketone 
3-penten-2-one 
1 -acetyl-1 -cyclopentene 
2,4-hexadienal 
1-cyclohexene carboxaldehyde 
The next step was to make sure that the nitro group could be successfully reduced to 
an amino group. The selective reduction of an aliphatic nitro group in the presence of an 
unsaturated ester has relatively little literature precedent.14 The methyl, cyclopentyl and 
phenyl groups were chosen as these would represent the three different types of analogs 
which either had an aliphatic, cyclic or aromatic substituent. The reduction was successfully 
carried out using tin and concentrated hydrochloric acid in ethanol.15 The amino analogs 17, 
18 and 19 were obtained from nitro analogs 12a, 12g, and 12c in 67 %, 86 % and 72 % 
yields, respectively. 
19 
11 
Two a,P-unsaturated aldehydes were made in order to give more examples of Tamiflu 
analogs. Their reaction with phosphonate 13 and DBU did not result in formation of the 
desired analogs. In one case, another double bond was introduced via elimination, compound 
20 and in the other case, there was an additional elimination of the nitro group to give 
compound 21. 
N02 O C02Et 
IJ DBU 
CH2CI2 
(Et0)2P/^C02Et BnQ2C^ ° °c^ 50 °c 
O 
13 
N02 o C02Et 
OO2BII 
DBU 
COo Et 
CH2CI2 
(EtO)2P/ ^C02Et Et02C' 0 °C— 50 °C 
O 
13 
Alternate Route 
The above route for making the analogs has the disadvantage that cis/trans isomers 
may be formed. The diastereomers may be separated for the most part by chromatography. 
However, some of the diastereomers have the same Rf value. This leads to a decrease in the 
amount of the desired isomer being obtained. The next thing to do was to plan another model 
system for the synthesis of Tamiflu. This new route involved the synthesis of an isoxazoline. 
The first isoxazoline was made from methyl 4-nitrobutyrate, ethyl crotonate and phenyl 
isocyanate in the presence of triethylamine. The reaction involves formation of a nitrile oxide 
that is involved in a cycloaddition with a dipolarophile.16,17 The cycloaddition is also 
concerted. It was later discovered that regioisomers are formed using this method and the 
major isomer is the undesired regioisomer. 
12 
NO2 + 
PhNCO 
/=o 
(desired product) 
The next step was to look for a route where the isoxazoline could be made 
regioselectively via a nitrile oxide. Isoxazolines can be made regioselectively by using nitro 
alkanes, dipolarophiles and a catalytic amount of DMAP.18 The same reaction conditions 
were applied to methyl 4-nitrobutyrate and ethyl aery late, but the desired product was not 
obtained. The methyl 4-nitrobutyrate did not react and was the main compound present by 
proton NMR spectroscopy. Modifications to the reaction, which included changing the 
solvent, resulted in the desired product. The yield was further increased to 76% by using 
Shimizu's method.19 That was achieved by using methyl 4-nitrobutyrate, ethyl acrylate, ethyl 
chloroformate, and triethylamine using chloroform as the solvent.19 Due to the nature of the 
dipolarophile a mixture of diastereomers is obtained. 
NO2 + 
O 
A 
TEA 
ciAD^ 
chloroform 
76% 
13 
The mechanism for formation of the nitrile oxide and the cycloaddition is shown below. 
© 
-M -Cl 
O à. 
-EtOCOOH 
Once the isoxazoline was made, the next step was to cyclize the isoxazoline that 
contained two ester groups to a six-membered ring. Several attempts were made to alkylate 
the imine in the ring using reagents such as dimethyl sulfate 20 and tri ethyl oxonium 
tetrafluoroborate.21 The methylation was achieved successfully with methyl triflate. 
After this, the iminium salt was reduced to an amine. Reduction using NaBH4 
resulted in the loss of one of the ester groups. The desired reduction was achieved with 
NaBH3CN under acidic conditions where a mixture of diastereomers was obtained. The main 
disadvantage of this reaction is that it resulted in a low yield. 
NaBhUCN 
O MeOH 
z=o 
Once the amine was formed, the cyclization to the six-membered ring was attempted 
under basic conditions using NaOMe/MeOH, or zBuOK/zBuOH. None of the conditions used 
14 
resulted in successful cyclization of the amine. The use of base facilitates epimerization, 
which would later lead to cyclization to obtain the desired product. The main advantage of 
successful cyclization is that the compound formed has the desired stereochemistry of 
Tamiflu. 
Summary 
This work has shown the synthesis of eight nitro analogs of Tamiflu in yields from 24 
% to 74 % and three amino analogs in yields from 67 % to 86 %. The most attractive feature 
of this synthesis is that it only involves 2 steps. The reaction seems to work best with a,P-
unsaturated aldehydes or ketones that contain trans carbon-carbon double bonds. In addition 
the analogs have the ester, amino and carbon-carbon double bond functionalities, which are 
key components in Tamiflu. 
An alternate route for the synthesis of Tamiflu provides a model system from which 
the desired product may be synthesized. An isoxazoline, which is a key intermediate for this 
route, has been synthesized in four steps. The main advantage of this route is that if the 
cyclization is achieved successfully then it provides the desired stereochemistry for the 
pentyl ether that could be later introduced at position three and the amino group at position 
five. 
O 
NHAc 
Tamiflu 
15 
Experimental Section 
Unless otherwise noted, materials were obtained from commercial suppliers and used without 
purification. Tetrahydrofuran was distilled from sodium benzophenone ketyl. 
Dichloromethane and benzene were distilled over calcium hydride. All experiments were 
performed under argon atmosphere unless otherwise noted. Nuclear magnetic resonance 
experiments were performed with either a Varian 300 MHz or Bruker 400 MHz instrument. 
All chemical shifts are reported relative to CDCI3 (7.27 ppm for *H and 77.23 ppm for 13C), 
unless otherwise noted. Coupling constants (J) are reported in Hz with abbreviations: s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet. High resolution mass spectra were 
recorded on a Kratos model MS-50 spectrometer and low resolution mass spectra were 
performed with a Finnegan TSQ700 mass spectrometer. Standard grade silica gel (60 A, 32-
63 |im) was used for a flash column chromatography. 
Ethyl 2-(diethoxyphosphoryl)acrylate. The aery late was prepared by modified literature 
procedure.10 To a solution of paraformaldehyde (3.3 g, 110 mmol) in MeOH (225 mL) was 
added 20 drops of piperidine. The reaction mixture was refluxed for 30-45 min to create a 
homogeneous mixture. Triethylphosphonoacetate (13.3 ml) was added in one portion and the 
mixture was refluxed for 30 h. After 15 h, additional portions of paraformaldehyde (3.3 g, 
110 mmol) and piperidine (20 drops) were added. The solution was cooled to rt. and 
evaporated. To a solution of the crude oil dissolved in toluene (150 mL) was added PTSA 
(0.64 g) and the reaction mixture was refluxed under a Dean-Stark separator for 30 h. After 
15 h, an additional portion of PTSA (0.64 g) was added. Progress for both parts of the 
reaction was monitored by *H NMR. The solution was cooled to rt. and evaporated to give a 
brown oil, which was used in the next step without further purification: *H NMR (300 MHz, 
C D C I 3 )  ô  1 . 1 8 - 1 . 2 5  ( 9 H ,  m ) ,  3 . 9 7 - 4 . 1 2  ( 4 H ,  m ) ,  4 . 1 3  ( 2 H ,  q , J =  7 . 2  H z ) ,  6 . 5 8  ( 1 H ,  d d ,  J  =  
20.4, 1.8 Hz), 6.80 (1H, dd, J= 42.3, 1.8 Hz). 
16 
Ethyl 2-diethoxyphosphoryl-4-nitrobutyrate (13). To a solution of 1.2 M NaOMe (17.6 
mL, 21.2 mmol) at 0 °C under argon was added a solution of nitromethane (2.6 g, 42.4 
mmol) in MeOH (3 mL). The reaction mixture was stirred for 1 hr and allowed to warm to rt. 
After cooling to 0 °C for 10 min, a solution of ethyl 2-(diethoxyphosphoryl)acrylate (5 g, 
21.2 mmol) in MeOH (5 mL) was added to the reaction flask drop wise. The reaction mixture 
was slowly warmed to rt. and stirred for 3-4 h. The reaction mixture was filtered to remove 
the precipitate that formed during the course of the reaction, neutralized to pH 7 with acetic 
acid, and evaporated. A brown solid was obtained and this was dissolved in EtOAc. The 
resulting mixture was filtered, and the filtrate evaporated to give a brown oil. Column 
chromatography on silica gel (50% EtOAc/hexanes) provided 3.4 g (54 % yield) of a yellow 
oil for the 2 steps: JH NMR (300 MHz, CDC13) ô 1.13-1.23 (9H, m), 2.40 (2H, m), 2.93 (1H, 
m), 3.97-4.11 (6H, m), 4.37 (2H, m); 13C NMR (400 MHz, CDC13) ô 14.1, 16.4,41.5,42.8, 
62.1, 63.2, 73.0, 167.9; HRMS calcd for CioH2oN07P 297.0977, found 297.0982. 
General Procedure for analogs 
To a solution of (^-unsaturated aldehyde or ketone (0.34 mmol) in CH2CI2 was added DBU 
(0.64 mmol). The reaction mixture was cooled to 0 °C. After 10 min, a solution of 13 (0.34 
mmol) in CH2CI2 was added drop wise to the reaction mixture and allowed to warm to rt. over 
2 h. The reaction mixture was then heated at 50 °C for another 2 h. 2N HCl was added to the 
reaction mixture after cooling to rt. The organic layer was washed one more time with 2N 
HCl and once with brine, dried (Mg2S04) and evaporated to give an orange oil. Column 
chromatography on silica gel yielded the product. 
4-Methyl-5-nitro-l-cyclohexenecarboxylic acid, ethyl ester (12a). (53 mg, 74%) of a 
yellow oil: JH NMR (300 MHz, CDC13) ô 1.04 (3H, d, J= 6.3 Hz), 1.27 (3H, t, J= 6.9 Hz), 
1.60-2.10 (1H, m), 2.34 (1H, m), 2.50 (1H, m), 2.85 (1H, m), 2.94 (1H, m), 4.17 (2H, q,J = 
7.2 Hz), 4.37 (1H, m), 6.90 (1H, bs); 13C NMR (300 MHz, CDC13) ô 15.3, 17.8, 29.1, 32.6, 
61.1, 88.2, 127.1, 137.6, 166.0; HRMS calcd for C10H15NO4 213.1001, found 213.1005. 
17 
3,4-Dimethyl-5-nitro-l-cyclohexenecarboxylic acid, ethyl ester (12b). (18 mg, 24%): *H 
NMR (400 MHz, CDC13) ô 1.00 (3H, d, J = 6.9 Hz), 1.06 (3H, d, J = 6 Hz), 1.19-1.22 (4H, 
m), 1.29-1.35 (6H, m), 1.76 (1H, bd, J= 12 Hz), 1.90 (1H, m), 2.20 (2H, m), 2.38 (2H, m), 
2.72-2.92 (3H, m), 2.99-3.08 (1H, m), 4.21 (4H, q,J= 6.9 Hz), 4.43 (1H, m), 4.70 (1H, m), 
6.77 (1H, bs), 6.89 (1H, bs); LRMS for C10H15NO4 227.26 g/mol 64 (6%), 78 (26%), 90 
(37%), 106 (100%), 122 (31%), 135 (15%), 151 (53%), 165 (22%), 181 (28%), 227 (1%). 
4-Phenyl-5-nitro-l-cyclohexene carboxylicacid, ethyl ester (12c). (55 mg, 59 %): 'HNMR 
(300 MHz, CDCI3) ô 1.26 (3H, t,J= 7.2 Hz), 2.47-2.60 (1H, m), 2.72 (1H, m), 2.97 (1H, m), 
3.10 (1H, m), 3.43 (1H, m), 4.21 (2H, q,J= 7.2 Hz), 4.93 (1H, m), 7.06 (1H, m), 7.21-7.33 
(5H, m); NMR (300 MHz, CDCI3) 8 14.5, 30.0, 33.2, 43.5, 61.2, 87.0, 127.3, 127.5, 
128.2, 129.2, 137.8, 139.3, 165.8; HRMS calcd for C15H17NO4 275.1158, found 275.1161. 
2-Methyl-4-phenyl-5-nitro-l-cyclohexenecarboxylic acid, ethyl ester (12d). (25 mg, 
26%): JH NMR (400 MHz, CDC13) ô 1.29 (3H, t,J= 7.2 Hz), 2.11 (3H, s), 2.50-2.65 (2H, 
m), 2.94 (1H, m), 3.11 (1H, m), 3.42 (1H, m), 4.20 (2H, q,J= 7.2 Hz), 4.92 (1H, m), 7.20-
7.33 (5H, m); NMR (300 MHz, CDCI3) ô 14.5, 21.4, 32.1, 41.4, 44.0, 60.8, 87.0, 120.6, 
127.4, 128.1, 129.2, 139.3, 146.3, 166.9; HRMS calcd for CI6HI9N04 289.1314, found 
289.1317. 
4-(2-Furyl)-5-nitro-l-cyclohexenecarboxylic acid, ethyl ester (12e). (27 mg, 60%): *H 
NMR (400 MHz, CDC13) ô 1.30 (3H, t, J= 6.9 Hz), 2.69 (2H, m), 2.98 (2H, m), 3.64 (1H, 
m), 4.21 (2H, q,J= 7.2 Hz), 4.92 (1H, m), 6.15 (1H, d, J= 3.2 Hz), 6.30 (1H, m), 7.03 (1H, 
m), 7.36 (1H, m); NMR (400 MHz, CDCI3) ô 14.5, 28.9, 29.4, 36.6, 61.2, 84.9, 107.6, 
110.6, 126.9, 136.8, 142.7, 152.0, 165.7; HRMS calcd for C13H15NO5 265.0956, found 
265.0961. 
4-Heptyl-5-nitro-l-cyclohexenecarboxylic acid, ethyl ester (12f). (32 mg, 64%): 'HNMR 
(400 MHz, CDCI3) ô 0.86 (3H, t, J= 7.2 Hz), 1.27-1.33 (14H, m), 1.41 (1H, m), 2.05 (1H, 
m), 2.22 (1H, m), 2.50 (1H, m), 2.89-2.93 (2H, m), 4.19 (2H, q, J= 7.2 Hz), 4.49 (1H, m), 
18 
6.95 (1H, m); NMR (400 MHz, CDClg) ô 14.3, 14.5, 22.8, 26.3, 28.7, 29.3, 29.6, 29.7, 
32.0, 36.2, 61.1, 86.8, 126.9, 137.5, 166.0; HRMS calcd for Ci6H27N04 297.1940, found 
297.1944. 
2,3,3a,4,5,7a-Hexahydro-4-nitro-6-indenecarboxylic acid, ethyl ester (12g). (36 mg, 
45%): !H NMR (400 MHz, CDC13) ô 1.28 (3H, t, J= 6.9 Hz), 1.38-1.48 (2H, m), 1.80-1.90 
(3H, m), 1.98-2.10 (2H, m), 2.18 (1H, m), 2.90 (1H, m), 3.08 (1H, m), 4.18 (2H, q,J= 7.2 
Hz), 4.60 (1H, m), 7.08 (1H, m); 13C NMR (400 MHz, CDC13) ô 14.5, 22.2, 27.0, 28.4, 31.5, 
44.6, 46.7, 61.1, 86.8, 128.5, 140.6, 166.1; HRMS calcd for C12H17NO4 239.1158, found 
239.1160. 
l,3,3a,4,5,7a-Hexahydro-4-nitro-6- benzo[c]thiophenecarboxylic acid, ethyl ester (12h). 
(25 mg, 36%): JH NMR (300 MHz, CDC13) Ô 1.29 (3H, T, J =  7.2 Hz), 2.38 (1H, m), 2.70 
(2H, m), 2.98 (2H, m), 3.12-3.25 (3H, m), 4.21 (2H, q, J= 7.2 Hz), 4.69 (1H, m), 7.00 (1H, 
bs); NMR (400 MHz, CDCI3) ô 14.5, 31.4, 32.2, 33.3, 46.9, 48.1, 61.5, 86.1, 129.2, 
137.4, 165.6; HRMS calcd for C11H15NO4S 257.0756, found 257.0722. 
General Procedure for Reduction of the Nitro Analogs 
To a solution of the nitro analog (1 equiv.) in EtOH was added Sn (5 .3 equiv). The reaction 
was heated to 70 °C and 12 M HCl (54 equiv.) was added. The reaction mixture was refluxed 
for 20 min and cooled to rt. The solution was made weakly basic with 2M NaOH and 
extracted with EtOAc. The combined organic layers were washed once with brine, dried 
(Mg2SÛ4) and evaporated to give a yellow oil. Flash column chromatography on silica gel 
yielded the product. 
4-Methyl-5-amino-l-cyclohexenecarboxylic acid, ethyl ester (17). (29 mg, 67%): *H NMR 
(300 MHz, CDCI3) ô 1.01 (3H, d, J= 7 Hz), 1.26 (3H, t, J= 6.9 Hz), 1.46-1.57 (1H, m), 
1.82-1.98 (2H, m), 1.99-2.08 (1H, m), 2.22-2.48 (2H, m), 2.57-2.70 (2H, m), 4.14 (2H, q,J = 
7.2 Hz), 6.88 (1H, bs); NMR (400 MHz, CDCI3) ô 14.5, 18.2, 33.4, 33.5, 35.1, 52.3, 
60.6, 129.0, 138.3, 167.3; HRMS calcd for Ci0Hi7NO2 183.1259, found 183.1262. 
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2,3,3a,4,5,7a-Hexahydro-4-amino-6-indenecarboxylic acid, ethyl ester (18). (25 mg, 86 
%): NMR (400 MHz, CDC13) ô 1.27 (3H, t, J= 6.9 Hz), 1.33-1.38 (1H, m), 1.38-1.44 
(1H, m), 1.50-1.62 (1H, m), 1.73-1.83 (2H, m), 1.88-2.02 (2H, m), 2.03-2.17 (2H, m), 2.80-
2.84 (1H, bs), 2.84-2.89 (1H, bs), 2.94-3.03 (1H, m), 3.04-3.14 (1H, m), 4.16 (2H, q, J= 7.2 
Hz), 7.05 (1H, bs); NMR (400 MHz, CDClg) 8 14.5, 22.5, 27.2, 28.3, 31.3, 45.4, 46.0, 
52.4, 60.7, 130.1, 141.2, 167.3; HRMS calcd for C12H19NO2 209.1416, found 209.1419. 
4-Phenyl-5-amino-l-cyclohexenecarboxylic acid, ethyl ester (19). (34 mg, 72 %): *H 
NMR (400 MHz, CDC13) ô 1.27 (3H, t, J= 7.2 Hz), 2.17-2.28 (1H, m), 2.32-2.48 (2H, m), 
2.52-2.62 (1H, m), 2.63-2.72 (1H, m), 2.82 (1H, bs), 2.86 (1H, bs), 3.18-3.26 (1H, m), 4.17 
(2H, q,J= 7.2 Hz), 7.00 (1H, bs), 7.21-7.27 (3H, m), 7.29-7.35 (2H, m); 13C NMR (400 
MHz, CDCI3) ô 14.5, 33.0, 34.3, 47.6, 51.4, 60.8, 127.3, 127.9, 128.1, 129.2, 138.5, 142.4, 
167.0; HRMS calcd for Ci5Hi9N02 245.1416, found 245.1420. 
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CHAPTER 2 
Extraction of Prunella Vulgaris 
Introduction 
Dietary botanical supplements are used by about 7% of the American population as 
presumed preventatives and for the treatment of diverse diseases, such as depression and 
viral infections.1 Despite the extensive use of these supplements, scientific studies to 
understand the biological properties of the compounds present in these plant extracts are 
limited and the efficacy of many of the supplements is unclear. The Iowa Botanical 
Supplement Research Center has been conducting anti-viral and anti-inflammatory studies on 
the Prunella species, which exhibits both types of activities. 
Background 
There are a few drugs that have emerged for HIV treatment and include nucleoside 
and non-nucleoside reverse-transcriptase inhibitors and protease inhibitors.2 One example of 
this class of drugs is AZT (zidovudine), which is a nucleoside inhibitor and prevents HIV 
replication. The main drawback of HIV treatment is the development of viral strains that are 
resistant to the existing drugs and drug toxicity.3 As a result, there is an on-going effort in the 
search for new compounds that are active against HIV. One of the sources for promising new 
HIV compounds is Chinese herbs, which are known to have anti-viral activity. Prunella 
vulgaris, Prunella laciniata and Prunella orientalis are representative species of the Prunella 
(Lamiaceae) genus which have been used in the treatment of the common cold, diarrhea, 
rheumatoid arthritis and cardiac arrhythmia.4 The polar fraction of Prunella vulgaris also 
displays specific activity against the herpes simplex virus type 1 and 2.5 Due to the wide 
variety of biological activity that Prunella vulgaris exhibits it was of particular interest and 
soxhlet ethanol extracts were tested for activity against HIV. 
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In addition to anti-viral activity, Prunella vulgaris extracts exhibit anti-
hypersensitive, anti-hyperglycemic, anti-allergic, anti-inflammatory and cytotoxic activities.6 
A 10 kDa sulfated polysaccharide obtained from aqueous extracts of Prunella vulgaris has 
already been shown to inhibit HIV-1 replication with low cytotoxicity.2'7 Phytochemical 
studies of Prunella vulgaris show that ethanol extracts contain saponins, sterols, triterpenoids 
and flavonoids.2 Ryu et al. tested the triterpenes, urosolic acid and 2a,3a-dihydroxyurs-12-
en-28-oic acid and reported that each exhibited anti-inflammatory and anti-allergic activity 
respectively.9 Rosmarinic acid, a major phenolic component of Prunella vulgaris, is known 
to have several biological effects, which are antimicrobial, anti-oxidative, anti-inflammatory 
and inhibitory.8 
'COOH 
HO' 
'COOH 
HO" 
ursolic acid 2a,3a-dihydroxyurs-12-en-28-oic acid 
OH 
HO. 
HOOC OH 
HO' 
rosmarinic acid 
The two main ways in which Prunella vulgaris may be extracted are either under aqueous 
conditions or using alcohols, such as methanol or ethanol. 
Extraction and Isolation 
The first soxhlet extraction of Prunella vulgaris was done on the dried aerial part, 
which included the stems, leaves and flowers using EtOH (absolute 200 proof) for about 36 
hours. The extract was concentrated under reduced pressure and stored at 0°C. The crude 
extract tested positive for anti-HIV activity and anti-inflammatory activity. The next step was 
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to isolate different fractions and this was achieved by preparative TLC using CH2CI2. One 
preparative plate was developed and 8 fractions were isolated from the preparative plate. 
There were four regions on the preparative TLC and each of these regions was divided into 
two regions, where the lower fractions were labeled Al, Bl, CI and Dl, and the upper 
fractions were labeled A2, B2, C2 and D2. These fractions were again tested for anti-HIV 
activity and anti-inflammatory activity. 
D2 ^ 
Dl • 
C2 • 
CI 
B2 • 
Bl 
A2. 
A1 
Anti-HIV Activity found in Prunella vulgaris 
Ethanol soxhlet extractions of dried Prunella vulgaris leaf and shoot material were 
tested for the ability to inhibit HIV replication. Non-cytotoxic concentrations of the extracts 
were effective at blocking HIV replication. The extract was fractionated into eight fractions, 
labeled 1 to 8, where fraction 1 corresponded to Al, fraction 2 to A2 through to fraction 8, 
which corresponded to D2. These fractions were tested against HIV and found to have some 
anti-viral activity across all fractions with two non-adjacent fractions, fraction 5 and 8, 
having the strongest anti-HIV activity with little associated cytotoxicity. This surprising 
result suggested that there are multiple components with anti-HIV activity present in 
Prunella vulgaris extracts. The data collected from this initial analysis is shown in Figure 1. 
The data collected on HIV replication and cytotoxicity are both represented in Figure 1. With 
regards to the HIV data the best results are obtained from a reduction in the HIV replication. 
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In the cytotoxcity study the data shows that no cell death is occurring because the % control 
levels are above or relatively close to 100 %. These studies still are on-going. 
c 
o 
o 
150% 
100% 
50% 
0% 
• cytotoxicity 
•  HIV 
1 
100 30 10 
extract (ug/ml) 
1 2 3 4 5 6 7 8 
fractions 
Figure 1. Ability of fractions from a P. vulgaris extract to inhibit HIV replication. The 
anti-HIV activity of the original extract is shown on the left hand side of the figure and the 
inhibitory activity of 10 ug/ml of each fraction is shown on the right. Cytoxicity is also 
shown for each treatment. 
A second extraction of Prunella vulgaris was later carried out in a similar manner. In 
this case, 41.5 grams of the aerial part was extracted. After this, an extraction was done on 
the root (5.49 grams that had been separated from the aerial part). Both extracts were 
concentrated under reduced pressure to give 4.06 grams from the aerial part and 264 
milligrams from the root. Part of the extract from aerial Prunella vulgaris was dissolved in 
acetone and developed on preparative TLC using CH2CI2. The twelve fractions isolated were 
washed from the silica gel of the preparative TLC using 1:1 EtOAc and CH2CI2 ,and were 
labeled A to L from the most polar fraction (A) to the least polar fraction (L). Each fraction 
was concentrated under reduced pressure and dissolved in DMSO without further 
purification. Studies on the second extraction are on-going. 
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Anti-inflammatory Activity of Prunella vulgaris 
The anti-inflammatory activity of Prunella vulgaris was investigated in cells with and 
without lipopolysaccharide (LPS) or endotoxin, which induces an inflammatory response. 
LPS is commercially available from Sigma Aldrich. The level of reduction was always 
compared to the control which in this case corresponded to the control for the media and 
DSMO. Media was what made the cells grow. Mouse macrophage cells were used and were 
grown in a culture that is commercially available. These were treated with the Prunella 
vulgaris crude extract (Figure 2) and after eight hours the prostaglandin E2 (PGE2) levels 
were observed. LPS was used to induce PGE2 production and the idea was to look for a 
reduction in the production of PGE2. There was a media control and a solvent control, 
represented by the first two sets of data in Figure 2. All three dose responses at 
concentrations of 136, 68 and 34 micrograms per milliliter were significant, even though at 
the lower concentrations of extract, there was less of an anti-inflammatory response. For the 
purpose of this experiment, the level of significance was determined by a p-value of < 0.05. 
An asterisk was placed above any set of data that showed significance. 
2.5 
2 
I 1-5 •> 
5 
C M  111 
Figure 2. Anti-inflammatory activity of the Prunella vulgaris crude extract 
n=4 
• no LPS 
+ LPS 
media media + DMSO 136 ug/ml 68 ug/ml 34 ug/ml 
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A similar experiment was done on the fractions obtained from the preparative TLC of 
the crude extract. In addition to the other controls, there was a positive control represented by 
the last data set (labeled Quercetin), which ensured that the assay was working properly. 
Quercetin is a flavanoid that is known to exhibit anti-inflammatory activity. The fraction 
which showed the most significant anti-inflammatory response in Figure 3 was fraction B2 
obtained from the first extraction of Prunella vulgaris. 
• no LPS • + 1 ug/ml LPS 
r 
r* 
\ 
1 L 
| n=3 
J 
r 
|i fM if A if r* 
I I 
0 
| 
1 r*l 
media media + A.1 A.2 B.1 B.2 C.1 C.2 D.1 0.2 10 uM 
DMSO Quercetin 
Figure 3. Anti-inflammatory activity of the first Prunella vulgaris fractions 
Figure 4 shows data for a cytotoxic study that was done on the first set of Prunella 
vulgaris extractions. Both the crude extract, at different concentrations, and the fractions 
obtained from preparative TLC were analyzed for cytotoxicity. The control used for this set 
of data was the media and DMSO. A reduction below this level resulted in cell death. Several 
fractions indicated a significant level of cytotoxicity. Fraction B2 showed no cytotoxicity and 
this data corresponds very well with the data obtained for the anti-inflammatory response. 
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Figure 4. Cytotoxicity from the first Prunella vulgaris extraction 
An analysis on the anti-inflammatory activity for the second extraction of Prunella 
vulgaris was also done. Figures 5 and 6 show the data obtained. In this case, fractions A, I, J, 
K and L all showed significant levels of anti-inflammatory activity. Fraction I showed the 
most significant anti-inflammatory response with reduction occurring with and without the 
presence of LPS. 
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Figure 5. Anti-inflammatory activity observed for the second set of Prunella vulgaris 
fractions 
None of the fractions from the second extraction showed significant levels of 
cytotoxicity. There are other anti-inflammatory studies done on the Prunella species that 
have produced similar results where there is a reduction in the anti-inflammatory response 
even though the mechanism of immune activity has not yet been determined.4 The active 
components in the Prunella extracts and which pathways they affect in the immune response 
have yet to be determined. 
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Figure 6. Cytotoxicity from the second Prunella vulgaris extraction 
Summary 
Prunella vulgaris was shown to have both anti-HIV and anti-inflammatory activity 
with low levels of cytoxicity. Fractions 5 and 8 from the first extraction showed the strongest 
anti-HIV activity with little associated cytotoxicity. Studies on the anti-HIV activity of the 
second extraction are still on-going. In the anti-inflammatory study, fraction B from the first 
extraction showed the strongest response. In the second extraction, fraction I had the best 
anti-inflammatory response. 
Experimental Section 
Unless otherwise noted, materials were obtained from commercial suppliers and used without 
purification. Ethanol soxhlet extraction was done on both the aerial part and root of Prunella 
vulgaris over 36 hours. All crude extracts are stored at 0 °C. Preparative TLC was carried out 
on Analtech silica gel plate (1000 microns) with UV 254 nm. The developing solvent used 
was CH2CI2. The fractions isolated were washed from the preparative TLC plate silica gel 
using 1:1 EtOAc and CH2CI2 
n=4 
Media ABCDEFGH I JKL 
DMSO 
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Abbreviations 
DBU l,8-Diazabicyclo[5.4.0]-undec-7-ene 
THF Tetrahydrofuran 
NMR Nuclear magnetic resonance 
PTSA />Toluenesulfonic acid monohydrate 
TFA Trifluoroacetic acid 
DMAP 4-(Dimethylamino)pyridine 
DMSO Dimethyl sulfoxide 
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